Xenco Medical Expands its Global Reach with New Distribution Hubs in four High-growth Healthcare Markets
Widely recognized as one of the most disruptive healthcare innovators today, Xenco Medical has taken another step in its international growth with the launch of new distribution hubs across the United Arab Emirates, Saudi Arabia, Singapore and Oman to serve hospitals and surgical providers in the Middle East and Southeast Asia.
The expansion reflects increasing global demand for advanced orthopedic and surgical technologies as healthcare systems in these regions invest heavily in infrastructure, specialty care and digital transformation. By establishing localized distribution channels, Xenco Medical aims to improve product availability, speed to care and operational support for providers adopting its biomimetic implants, regenerative biomaterials and composite polymer surgical systems.
The company’s portfolio is built around logistics-optimized, single-use implants and instruments designed to simplify hospital workflows. For health systems, this model is intended to reduce the burden of sterilization, reprocessing and instrument management, challenges that continue to strain operating rooms as surgical volumes grow and staffing remains tight.
In addition to improving supply chain efficiency, the platform is designed to support more predictable and consistent surgical performance across sites. By standardizing implant and instrument readiness, hospitals may be able to reduce delays, shorten turnover times and improve overall operating room utilization.
“A testament to the universal resonance of our breakthrough technologies, we have been immensely excited by the enthusiastic embrace of Xenco Medical across global markets, demonstrating the ability of scientific advancements to traverse continents. We look forward to translating our growing presence in the Middle East and Southeast Asia into transformative patient outcomes,” said Xenco Medical Founder and CEO Jason Haider.
A central part of the company’s offering is its TrabeculeX Continuum platform, which integrates regenerative biomaterials with artificial intelligence–enabled post-surgical monitoring. Using AI-driven pose assessment, the system allows clinicians to remotely track patient mobility, adherence to rehabilitation protocols and pain levels after surgery, creating a more continuous data stream between the hospital and the patient.
For hospitals in the Middle East and Southeast Asia, many of which are rapidly expanding outpatient and specialty surgery programs, the ability to monitor recovery outside the facility could help reduce readmissions, identify complications earlier and support value-based care initiatives.
The regions Xenco Medical is entering are among the fastest-growing healthcare markets globally, fueled by population growth, medical tourism and government-backed investments in modern hospital systems. As these providers look to adopt more efficient, technology-enabled care models, companies that can combine advanced clinical products with digital infrastructure and simplified logistics are gaining traction.
Xenco Medical’s single-use implant systems are also positioned as a sustainability and cost-management tool. By eliminating the need for repeated sterilization cycles and complex instrument reprocessing, the company says hospitals can reduce waste, labor requirements and the environmental footprint associated with traditional reusable systems.
The company’s recent international momentum follows a year of strong industry recognition. In 2025, Xenco Medical was named one of Fast Company’s World’s Most Innovative Companies for the second time, earned the World Economic Forum’s Award for Excellence in Governance and Leadership for Global Challenges, and received Medical Device/Diagnostics Company of the Year honors at the Trailblazer Awards in New York City, according to the company.
With its expanded network now spanning multiple regions, Xenco Medical is positioning itself as a global supplier of next-generation surgical technologies. As health systems in the Middle East and Southeast Asia continue to modernize and scale, the company’s growing footprint is expected to support wider adoption of data-driven, regenerative and efficiency-focused surgical care models.
